Importantly, this dependency creates a therapeutic vulnerability: pharmacological inhibition of antioxidant components—such as GPX4, Trx1, TrxR, and SOD1—can tip the balance toward lethal oxidative stress and selectively kill tumor cells. The gene discussed is TXN; the disease is neoplasm.